For research use only. Not for therapeutic Use.
MM 54 (compound 5) is a competitive antagonist at APJ, with an IC50 of 93 nM. MM 54 behaves as a potent and selective inhibitor of apelin binding and APLNR activation[1][2].
MM 54 inhibits more than 95% of apelin binding to APLNR at the dose of 10 µM[2].
MM 54 (2 mg/kg, ip, bi-weekly for 4 weeks) possesses anti-tumor activity in glioblastoma models with no obvious toxicity[2].
Catalog Number | P000327 |
CAS Number | 1313027-43-8 |
Molecular Formula | C70H121N29O15S4 |
Purity | ≥95% |
Reference | [1]. N J Maximilian Macaluso, et al. Discovery of a competitive apelin receptor (APJ) antagonist. ChemMedChem. 2011 Jun 6;6(6):1017-23. [2]. Elizabeth Harford-Wright, et al. Pharmacological targeting of apelin impairs glioblastoma growth. Brain. 2017 Nov 1;140(11):2939-2954. |